Stefan Norin
Vermogen: 2 740 $ op 31-05-2026
Vermogen: 2 740 $ op 31-05-2026
Stefan Norin currently works at Oncopeptides AB, as Chief Medical Officer from 2023.
Mr. Norin also formerly worked at Medivir AB, as Associate Director-Clinical Research & development from 2017 to 2019 and Karolinska University Hospital, as Head-Lymphosection.
Mr. Norin received his doctorate degree from Karolinska Institutet.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 19-03-2026 | 13.975 ( 0% ) | 2 740 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| ONCOPEPTIDES AB | Hoofd Techniek/Wetenschap/O&O | 01-09-2023 |
| Bedrijven | Functie | Einde |
|---|---|---|
| MEDIVIR AB | Hoofd Techniek/Wetenschap/O&O | 01-03-2019 |
Karolinska University Hospital
Karolinska University Hospital Hospital/Nursing ManagementHealth Services Provides hospital services | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
Medivir AB
Medivir AB Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Karolinska Institutet
Karolinska Institutet Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oncopeptides AB
Oncopeptides AB Pharmaceuticals: MajorHealth Technology Develops chemotherapeutic pharmaceuticals of compounds for cancer treatment | Health Technology |
Karolinska University Hospital
Karolinska University Hospital Hospital/Nursing ManagementHealth Services Provides hospital services | Health Services |
Kies jouw editie
Alle financiële informatie op nationaal niveau